FDA Grants Accelerated Approval to Umbralisib for Two Indications

On February 5, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to umbralisib for the following indications:

• Adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen

• Adult patients with relapsed or refractory follicular lymphoma who have received at least three prior lines of systemic therapy.

Read the FDA announcement.

Read TG Therapeutics' announcement.

Posted 2/8/2021